Key result
The presence of antiphospholipid antibodies in carriers of Factor V Leiden and/or prothrombin G20210A gene mutations increased the risk of developing thromboembolic events 4.4-fold.
Why the study?
What risk factors predispose carriers of Factor V Leiden and/or prothrombin G20210A gene mutations to develop thromboembolic events and adverse outcomes of pregnancy?
Population
217 carriers of Factor V Leiden and/or prothrombin G20210A gene mutations at two tertiary centers.
Comparison
Presence of risk factors including… vs Asymptomatic carriers (controls).
Design
Case-control
Authors
Loading...
May support closer monitoring in mutation carriers with antiphospholipid antibodies; leaves open whether screening or prophylaxis improves outcomes.
Case-Control (n=217)
Yes
What risk factors predispose carriers of Factor V Leiden and/or prothrombin G20210A gene mutations to develop thromboembolic events and adverse outcomes of pregnancy?
Odds Ratio: 4.4
The presence of antiphospholipid antibodies and postoperative state are significant risk factors for thromboembolic events and adverse pregnancy outcomes in carriers of Factor V Leiden and/or prothrombin G20210A mutations.
DeSancho et al. (2009) conducted a case-control in Factor V Leiden and/or prothrombin G20210A gene mutations (n=217). Antiphospholipid antibodies vs. Absence of antiphospholipid antibodies was evaluated on Thromboembolic events (4.4-fold increase). The presence of antiphospholipid antibodies in carriers of Factor V Leiden and/or prothrombin G20210A gene mutations increased the risk of developing thromboembolic events 4.4-fold.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: